Advertisement

Urological Research

, Volume 25, Supplement 1, pp S25–S30 | Cite as

p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma

  • H. Moch
  • G. Sauter
  • T. C. Gasser
  • N. Buchholz
  • L. Bubendorf
  • J. Richter
  • F. Jiang
  • A. Dellas
  • M. J. Mihatsch
Original Paper

Abstract

The clinical course of renal cell carcinoma (RCC) is highly variable. Overexpression of the p53 protein has been suggested as a possible prognostic parameter in RCC. Overexpression of the mdm-2 oncogene product has been shown to interact with the p53 function. To investigate the immunohistochemical overexpression of mdm-2 protein in comparison with that of p53 protein in RCC, 50 nonpapillary pT3 RCCs were immunostained for p53 protein (DO-7) and mdm-2 (1172). Tumor growth fraction (Ki-67 labeling index; MIB-1) was determined by immunohistochemistry. p53 positivity was detected in 16% of tumors. mdm-2 overexpression was seen in 30% of RCCs. There was a significant association between p53 and mdm-2 immunostaining (P=0.0006), suggesting that mdm-2 protein may contribute to p53 protein stabilization in RCC. p53 overexpression was associated with a high Ki-67 LI (P=0.0002), suggesting that p53 overexpression is involved in growth control in RCC. Survival analysis showed that Ki-67 LI (P=0.04) and p53 overexpression were associated with poor prognosis (P=0.0021), whereas mdm-2 overexpression was not related to patient outcome (P=0.73). A Cox regression analysis revealed tumor stage (P<0.001) and p53 overexpression (P<0.05) to be independent prognostic parameters. It is concluded that p53 but not mdm-2 may be of practical relevance in predicting patient prognosis in RCC.

Key words

Renal cell carcinoma Prognosis p53 mdm-2 Survival Proliferation 

References

  1. 1.
    Devesa S, Silverman D, McLaughlin J (1990) Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1:133PubMedGoogle Scholar
  2. 2.
    Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531PubMedGoogle Scholar
  3. 3.
    Hall P, Lane D (1994) p53 in tumor pathology: Can we trust immunocytochemistry? J Pathology 172:1Google Scholar
  4. 4.
    Uhlman D, Nguyen P, Manivel J, et al. (1994) Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86:21470Google Scholar
  5. 5.
    Oda H, Nakarsuru Y, Ishikawa T (1995) Mutations of the p53 gene and p53 overexpression are associated with sarcomatoid transformation in renal cell carcinoma. Cancer Res 55:658PubMedGoogle Scholar
  6. 6.
    Zambetti G, Levine A (1993) The mdm-2 oncogene can overcome wild-type and mutant p53. FASEB J 7:855PubMedGoogle Scholar
  7. 7.
    Momand J, Zambetti P, Olsen D, George D, Levine A (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated trans activation. Cell 69:1237–1245PubMedGoogle Scholar
  8. 8.
    Leach F, Tokino T, Meltzer P, et al. (1993) p53 mutation and mdm-2 amplification in soft tissue sarcomas. Cancer Res 53:2231PubMedGoogle Scholar
  9. 9.
    Reifenberger G, Liu L, Ichimur K, Schmidt E, Collins V (1993) Amplification overexpression of the mdm-2 gene in a subset of human maliginant gliomas without p53 mutations. Cancer Res 53:2736PubMedGoogle Scholar
  10. 10.
    Oliner J, Kinzler K, Melzer P, George D, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80PubMedGoogle Scholar
  11. 11.
    Weiss L, Gelb A, Medeiros L (1995) Adult renal epithelial neoplasms. Am J Clin Pathol 103:624PubMedGoogle Scholar
  12. 12.
    Thoenes W, Stoerkel S, Rumpelt H (1986) Histopathology and classification of renal cell tumors (adenomas, oncocytomas, and carcinomas): the basic cytological and histopatholog ical elements and their use for diagnostics. Pathol Res Pract 181:125PubMedGoogle Scholar
  13. 13.
    UICC (1992) TNM classification of malignant tumours, 4th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  14. 14.
    Moch H, Sauter G, Mihatsch M, Gudat F, Epper I, Waldman F (1994) p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 25:1346PubMedGoogle Scholar
  15. 15.
    Moch H, Sauter G, Moore D, Mihatsch M, Gudat F, Waldman F (1993) p53 and erbB-2 protein overexpression are early stage alterations in transitional cell carcinoma of the bladder. Virchows Arch A 423:329Google Scholar
  16. 16.
    Bubendorf L, Sauter G, Moch H, et al. (1996) Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557PubMedGoogle Scholar
  17. 17.
    Gerdes J, Lemke H, Baisch H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710PubMedGoogle Scholar
  18. 18.
    Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 238Google Scholar
  19. 19.
    Fuhrman S, Lasky L, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655PubMedGoogle Scholar
  20. 20.
    Bot F, Godschalk J, Krishnadath K, van der Kwast T, Bosman F (1994) Prognostic factors in renal-cell carcinoma: immunohistochemical detection p53 protein versus clinico-pathological parameters. Int J Cancer 57:634PubMedGoogle Scholar
  21. 21.
    Kamel D, Turpeenniemi-Hujanen T, Vahakangas K, Paakko P, Soini Y (1994) Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology 25:339PubMedGoogle Scholar
  22. 22.
    Lipponen P, Eskelinen M, Hietala K, Syrjanen K, Gambetta R (1994) Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int J Cancer 57:275PubMedGoogle Scholar
  23. 23.
    Chemeris G, Loktinov A, Rempel A, Schwarz M, Bannasch P (1995) Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch 426:563PubMedGoogle Scholar
  24. 24.
    Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K (1993) Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 150:1298PubMedGoogle Scholar
  25. 25.
    Imai Y, Strohmeyer T, Fleischhacker M, Slamon D, Koeffler H (1994) p53 mutations and mdm-2 amplification in renal cell cancers. Mod Pathol 7:766PubMedGoogle Scholar
  26. 26.
    Finlay C (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cel Biol 13:301Google Scholar
  27. 27.
    Cordon-Cardo C, Latres E, Drobjak M (1994) Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794PubMedGoogle Scholar
  28. 28.
    Moch H, Presti J, Sauter G, et al. (1996) Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56:27PubMedGoogle Scholar
  29. 29.
    Cordon-Cardo C, Latres E, Drobnjak M, et al. (1994) Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794PubMedGoogle Scholar
  30. 30.
    Marchetti A, Buttitta F, Girlando S, et al. (1995) Mdm2 gene alterations and mdm-2 protein expression in breast carcinomas. J Pathol 175:31PubMedGoogle Scholar
  31. 31.
    Chilosi M, Doglioni C, Montagna L, et al. (1994) Abnormal expression of the p53-binding protein mdm-2 in Hodgkin's disease. Blood 84:4295PubMedGoogle Scholar
  32. 32.
    Wiethege T, Voss B, Müller K (1994) Detection of mdm-2 proto-oncogene in paraffin embedded human bronchial epithelium. J Cancer Res Clin Oncol 120:252PubMedGoogle Scholar
  33. 33.
    Delahunt B, Bethwaite PB, Nacey JN, Ribas JL (1993) Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumor grade, mitotic index, and silver-staining nucleolar organizer region numbers. J Pathol 170:471PubMedGoogle Scholar
  34. 34.
    Delahunt B, Bethwaite PB, Thornton A, Ribas JL (1995) Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Cancer 75:2714PubMedGoogle Scholar
  35. 35.
    Eskelinen M, Lipponen P, Aitto OL, Hall O, Syrjanen K (1993) The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. Int J Cancer 55:547PubMedGoogle Scholar
  36. 36.
    de Riese W, Crabtree WN, Allhoff EP, et al. (1993) Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 11:1804PubMedGoogle Scholar
  37. 37.
    Larsson P, Roos G, Stenling R, Ljungberg B (1993) Tumor-cell proliferation and prognosis in renal-cell carcinoma. Int J Cancer 55:566PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • H. Moch
    • 1
  • G. Sauter
    • 1
  • T. C. Gasser
    • 2
  • N. Buchholz
    • 2
  • L. Bubendorf
    • 1
  • J. Richter
    • 1
  • F. Jiang
    • 1
  • A. Dellas
    • 3
  • M. J. Mihatsch
    • 1
  1. 1.Institute of PathologyUniversity of BaselBaselSwitzerland
  2. 2.Clinics of UrologyUniversity of BaselBaselSwitzerland
  3. 3.Clinics of GynecologyUniversity of BaselBaselSwitzerland

Personalised recommendations